GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 349-359 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2015CrossrefDirectly related103 citations

2014OpenAlexSupporting evidence968 citations

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

Anna Secher; Jacob Jelsing; Arian F. Baquero; Jacob Hecksher‐Sørensen; Michael A. Cowley; Louise S. Dalbøge; Gitte Hansen; Kevin L. Grove; Charles Pyke; Kirsten Raun; Lauge Schäffer; Mads Tang‐Christensen; Saurabh Verma; Brent M. Witgen; Niels Vrang; Lotte Bjerre Knudsen

Sep 8, 2014Journal of Clinical Investigation

2014OpenAlexSupporting evidence556 citations

Adverse Effects of GLP-1 Receptor Agonists

Theodosios D. Filippatos; Thalia Panagiotopoulou; Moses Elisaf

Jan 1, 2014The Review of Diabetic Studies

2014OpenAlexDirectly related594 citations

The Ethics of Childhood Obesity Treatment - from the Childhood Obesity Task Force (COTF) of European Association for the Study of Obesity (EASO)

Jens‐Christian Holm; Paulina Nowicka; Nathalie J. Farpour‐Lambert; Grace O’Malley; Maria Hassapidou; Ram Weiss; Jennifer L. Baker

Jan 1, 2014Obesity Facts

2013CrossrefDirectly related7 citations

Liraglutide pancreatitis: The ABCD nationwide liraglutide audit

REJ Ryder; KY Thong; AD Blann; SM Phillips; ND Barwell; CJG Kelly; C Semple; ML Cull; P Sen Gupta

Nov 1, 2013The British Journal of Diabetes & Vascular Disease

2011OpenAlexDirectly related352 citations

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

Alan J. Garber

Apr 22, 2011Diabetes Care

2011CrossrefDirectly related28 citations

Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies

B. Charbonnel; B. Cariou

Feb 1, 2011Diabetes, Obesity and Metabolism

2010OpenAlexDirectly related663 citations

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

Lotte Bjerre Knudsen; Lars Wichmann Madsen; Søren Andersen; Kasper Almholt; Anne Sietske de Boer; Daniel J. Drucker; C. F. Gotfredsen; Frederikke Lihme Egerod; Anne Charlotte Hegelund; Helene Jacobsen; Søren Dyring Jacobsen; Alan C. Moses; Anne‐Marie Mølck; Henriette Svarre Nielsen; Jette Nowak; Helene Solberg; Tu D. L. Thi; Milan Zdravkovic

Mar 4, 2010Endocrinology

2010OpenAlexDirectly related552 citations

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Masayuki Arakawa; Tomoya Mita; Kosuke Azuma; Chie Ebato; Hiromasa Goto; Takashi Nomiyama; Yoshio Fujitani; Takahisa Hirose; Ryuzo Kawamori; Hirotaka Watada

Jan 12, 2010Diabetes

2008OpenAlexSupporting evidence1,127 citations

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Michael A. Nauck; Anders Frid; Kjeld Hermansen; Nalini S. Shah; Tsvetalina Tankova; Ismail Mitha; Milan Zdravković; Maria Düring; David R. Matthews; for the LEAD-2 Study Group

Oct 17, 2008Diabetes Care

1995CrossrefSupporting evidence24 citations

Obesity Level and Attrition: Support for Patient‐Treatment Matching in Obesity Treatment

Matthew M. Clark; Barrie J. Guise; Raymond S. Niaura

Jan 1, 1995Obesity Research